Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing

被引：26

作者：

Baselga, J ^{[1
]}

机构：

[1] Vall Hebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2002年 / 13卷 / 01期

关键词：

D O I：

10.1093/annonc/mdf092

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：8 / 9

页数：2

共 17 条

[1] ANIDO J, 2001, P AN M AM SOC CLIN, V20, pA1712
[2] Baselga J, 2001, J CLIN ONCOL, V19, p41S
[3] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
Baselga, J
Tripathy, D
Mendelsohn, J
Baughman, S
Benz, CC
Dantis, L
Sklarin, NT
Seidman, AD
Hudis, CA
Moore, J
Rosen, PP
Twaddell, T
Henderson, IC
Norton, L
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
[4] BONNER JA, 2000, P AN M AM SOC CLIN, V19, pF5
[5] Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[6] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
Cobleigh, MA
Vogel, CL
Tripathy, D
Robert, NJ
Scholl, S
Fehrenbacher, L
Wolter, JM
Paton, V
Shak, S
Lieberman, G
Slamon, DJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648
[7] HARRIS AL, 1989, CANCER CEL, V7, P353
[8] MOULDER SL, 2001, P AN M AM SOC CLIN, V20, pA8
[9] Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
Normanno, N
Campiglio, M
De Luca, A
Somenzi, G
Maiello, M
Ciardiello, F
Gianni, L
Salomon, DS
Menard, S
[J]. ANNALS OF ONCOLOGY, 2002, 13 (01) : 65 - 72
[10] EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES AND THEIR RECEPTORS IN HUMAN MALIGNANCIES
SALOMON, DS
BRANDT, R
CIARDIELLO, F
NORMANNO, N
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1995, 19 (03) : 183 - 232

← 1 2 →